manilatimes7h
NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program
It is estimated that about 60,000 people in the U.S. are currently living with FTD. Up to 40% of FTD cases have a genetic component and the patient receiving troculeucel is known to carry the C9orf72 ...
health.wusf.usf.edu23h
As the U.S. steps back from global health, what role will China play?
With the U.S. withdrawing from the World Health Organization and rethinking foreign aid, China has an opportunity to play a ...